BridgeBio Pharma, (Germany) Technical Analysis
| 2CL Stock | EUR 64.46 2.00 3.01% |
As of the 4th of February, BridgeBio Pharma, shows the Downside Deviation of 2.32, mean deviation of 1.77, and Risk Adjusted Performance of 0.1174. BridgeBio Pharma, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BridgeBio Pharma, mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation to decide if BridgeBio Pharma, is priced correctly, providing market reflects its regular price of 64.46 per share.
BridgeBio Pharma, Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as BridgeBio, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to BridgeBioBridgeBio |
BridgeBio Pharma, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BridgeBio Pharma,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BridgeBio Pharma,.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in BridgeBio Pharma, on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding BridgeBio Pharma or generate 0.0% return on investment in BridgeBio Pharma, over 90 days. BridgeBio Pharma, is related to or competes with Rogers Communications, Ribbon Communications, Sabra Health, Zegona Communications, VIRGIN WINES, Bumrungrad Hospital, and Comba Telecom. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases More
BridgeBio Pharma, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BridgeBio Pharma,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BridgeBio Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.32 | |||
| Information Ratio | 0.1224 | |||
| Maximum Drawdown | 12.73 | |||
| Value At Risk | (3.47) | |||
| Potential Upside | 3.76 |
BridgeBio Pharma, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BridgeBio Pharma,'s standard deviation. In reality, there are many statistical measures that can use BridgeBio Pharma, historical prices to predict the future BridgeBio Pharma,'s volatility.| Risk Adjusted Performance | 0.1174 | |||
| Jensen Alpha | 0.3157 | |||
| Total Risk Alpha | 0.1659 | |||
| Sortino Ratio | 0.1218 | |||
| Treynor Ratio | 0.8692 |
BridgeBio Pharma, February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1174 | |||
| Market Risk Adjusted Performance | 0.8792 | |||
| Mean Deviation | 1.77 | |||
| Semi Deviation | 2.11 | |||
| Downside Deviation | 2.32 | |||
| Coefficient Of Variation | 664.91 | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.32 | |||
| Information Ratio | 0.1224 | |||
| Jensen Alpha | 0.3157 | |||
| Total Risk Alpha | 0.1659 | |||
| Sortino Ratio | 0.1218 | |||
| Treynor Ratio | 0.8692 | |||
| Maximum Drawdown | 12.73 | |||
| Value At Risk | (3.47) | |||
| Potential Upside | 3.76 | |||
| Downside Variance | 5.38 | |||
| Semi Variance | 4.46 | |||
| Expected Short fall | (1.88) | |||
| Skewness | 0.0258 | |||
| Kurtosis | 0.8815 |
BridgeBio Pharma, Backtested Returns
BridgeBio Pharma, appears to be very steady, given 3 months investment horizon. BridgeBio Pharma, secures Sharpe Ratio (or Efficiency) of 0.14, which signifies that the company had a 0.14 % return per unit of risk over the last 3 months. We have found thirty technical indicators for BridgeBio Pharma, which you can use to evaluate the volatility of the firm. Please makes use of BridgeBio Pharma,'s Downside Deviation of 2.32, risk adjusted performance of 0.1174, and Mean Deviation of 1.77 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BridgeBio Pharma, holds a performance score of 11. The firm shows a Beta (market volatility) of 0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BridgeBio Pharma,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding BridgeBio Pharma, is expected to be smaller as well. Please check BridgeBio Pharma,'s downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether BridgeBio Pharma,'s price patterns will revert.
Auto-correlation | 0.28 |
Poor predictability
BridgeBio Pharma has poor predictability. Overlapping area represents the amount of predictability between BridgeBio Pharma, time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BridgeBio Pharma, price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current BridgeBio Pharma, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 1.37 |
BridgeBio Pharma, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
BridgeBio Pharma, Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of BridgeBio Pharma, volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About BridgeBio Pharma, Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of BridgeBio Pharma on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of BridgeBio Pharma based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on BridgeBio Pharma, price pattern first instead of the macroeconomic environment surrounding BridgeBio Pharma,. By analyzing BridgeBio Pharma,'s financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of BridgeBio Pharma,'s intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to BridgeBio Pharma, specific price patterns or momentum indicators. Please read more on our technical analysis page.
BridgeBio Pharma, February 4, 2026 Technical Indicators
Most technical analysis of BridgeBio help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for BridgeBio from various momentum indicators to cycle indicators. When you analyze BridgeBio charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1174 | |||
| Market Risk Adjusted Performance | 0.8792 | |||
| Mean Deviation | 1.77 | |||
| Semi Deviation | 2.11 | |||
| Downside Deviation | 2.32 | |||
| Coefficient Of Variation | 664.91 | |||
| Standard Deviation | 2.31 | |||
| Variance | 5.32 | |||
| Information Ratio | 0.1224 | |||
| Jensen Alpha | 0.3157 | |||
| Total Risk Alpha | 0.1659 | |||
| Sortino Ratio | 0.1218 | |||
| Treynor Ratio | 0.8692 | |||
| Maximum Drawdown | 12.73 | |||
| Value At Risk | (3.47) | |||
| Potential Upside | 3.76 | |||
| Downside Variance | 5.38 | |||
| Semi Variance | 4.46 | |||
| Expected Short fall | (1.88) | |||
| Skewness | 0.0258 | |||
| Kurtosis | 0.8815 |
BridgeBio Pharma, February 4, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as BridgeBio stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.02 | ||
| Daily Balance Of Power | (1.67) | ||
| Rate Of Daily Change | 0.97 | ||
| Day Median Price | 65.06 | ||
| Day Typical Price | 64.86 | ||
| Price Action Indicator | (1.60) | ||
| Market Facilitation Index | 1.20 |
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma,'s price analysis, check to measure BridgeBio Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma, is operating at the current time. Most of BridgeBio Pharma,'s value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma,'s price. Additionally, you may evaluate how the addition of BridgeBio Pharma, to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |